Newsbenzinga
Why Iovance Biotherapeutics Stock Hit 52-Week High
· Published
Article summary
Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
An excerpt from the original article.
Comments —
Loading comments…